ClinicalTrials.gg

Program

rocbrutinib

Also written as “Rocbrutinib”, “LP-168 tablet” and “LP-168”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Sclerosis, Relapsing-Remitting · Waldenstrom Macroglobulinemia, led by 2 companies.

Furthest: phase 3, since Jan 13, 202615 company-led studies, 12 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lupeng Pharmaceutical1411 open or runningphase 3since Jan 13, 2026Feb 22, 2021Mar 31, 2027phase 1 · NCT04993690
Hansoh Pharmaceutical Group11 open or runningphase 2since Mar 4, 2025Mar 4, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 22, 2021First study: phase 1 study in Waldenstrom MacroglobulinemiaNew to Lupeng PharmaceuticalLupeng Pharmaceutical · NCT04775745 · 60 planned · United States
  2. Jul 27, 2021Phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT04993690 · 200 planned · China
  3. Jun 14, 2022Phase 1 study in Multiple SclerosisLupeng Pharmaceutical · NCT05432713 · 70 enrolled · China
  4. Jan 19, 2023Phase 2 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT05716087 · 62 enrolled · China
  5. Jun 15, 2023Phase 1 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT05917964 · 22 enrolled · China
  6. Nov 7, 2023Phase 1 study in Clinical PharmacologyLupeng Pharmaceutical · NCT06126861 · 6 enrolled · China
  7. Feb 1, 2024Phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT06251180 · 112 enrolled · China
  8. Mar 4, 2025Hansoh Pharmaceutical Group's first study: phase 2 study in Chronic UrticariaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06864507 · 150 planned · China
  9. Sep 16, 2025Phase 2 study in Lymphoma, Large B-Cell, DiffuseLupeng Pharmaceutical · NCT07189065 · 150 planned · China
  10. Jan 13, 20262 phase 3 studiesPhase 3 reachedLupeng Pharmaceutical · NCT07377578, NCT07342478
  11. Jan 16, 2026Phase 1 study in Clinical PharmacologyLupeng Pharmaceutical · NCT07374224 · 28 planned · China
  12. Apr 22, 2026Phase 1 study in DLBCLLupeng Pharmaceutical · NCT07570017 · 42 planned · China
  13. May 20, 2026Phase 2 study in Lymphoma, Mantle-CellLupeng Pharmaceutical · NCT07609862 · 92 planned · China
  14. Aug 7, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingLupeng Pharmaceutical · NCT07776743 · 30 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT04993690
  2. Jun 30, 2027Primary completion: phase 1 study in Lymphoma, B-CellLupeng Pharmaceutical · NCT06251180
  3. Dec 31, 2027Primary completion: phase 1 study in DLBCLLupeng Pharmaceutical · NCT07570017
  4. Dec 31, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseLupeng Pharmaceutical · NCT07189065

TargetBeta

BTK →read by rule
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07776743Multiple Sclerosis, Relapsing-Remitting · China2RecruitingLupeng PharmaceuticalJun 202830
NCT07609862Lymphoma, Mantle-Cell · China2RecruitingLupeng PharmaceuticalJun 30, 202992
NCT07570017DLBCL · China1RecruitingLupeng PharmaceuticalDec 31, 202742
NCT07374224Clinical Pharmacology · China1RecruitingLupeng PharmaceuticalJun 30, 202628
NCT07377578Lymphoma, Mantle-Cell · China3RecruitingLupeng PharmaceuticalMay 30, 2031394
NCT07342478Leukemia, B-Cell · United States, France3RecruitingLupeng PharmaceuticalOct 30, 2029306
NCT07189065Lymphoma, Large B-Cell, Diffuse · China2RecruitingLupeng PharmaceuticalDec 31, 2027150
NCT06864507Chronic Urticaria · China2Not yet recruitingHansoh Pharmaceutical GroupSep 27, 2026150
NCT06251180Lymphoma, B-Cell · China1Active, not recruitingLupeng PharmaceuticalJun 30, 2027112
NCT06126861Clinical Pharmacology · China1CompletedLupeng PharmaceuticalFeb 2, 20246
NCT05917964Lymphoma, Mantle-Cell · China1CompletedLupeng PharmaceuticalAug 21, 202322
NCT05716087Lymphoma, Mantle-Cell · China2Active, not recruitingLupeng PharmaceuticalDec 5, 202462
NCT05432713Multiple Sclerosis · China1CompletedLupeng PharmaceuticalNov 20, 202270
NCT04993690Lymphoma, B-Cell · China1RecruitingLupeng PharmaceuticalMar 31, 2027200
NCT04775745Waldenstrom Macroglobulinemia · United States1RecruitingLupeng PharmaceuticalDec 31, 202760

How it is read

Names in the registry

  • “Rocbrutinib”, 7 entries
  • “LP-168 tablet”, 3 entries
  • “LP-168”, 2 entries
  • “Lacutoclax+Rocbrutinib”, 1 entry
  • “Rocbrutinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.